Latest news and press releases about TG Therapeutics, Inc. (TGTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
Price
| Price | $55.85 |
| Market Cap | $8.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 18.34 |
| Price / Book | 13.11 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 82.36% |
| Operating Margin | 17.05% |
| Net Margin | 55.22% |
Related companies: ACLX · ALKS · ARWR · CRSP · IMVT · KRYS · KYMR
Explore sector: Healthcare · Biotechnology
More sections of TGTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks